Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

• Published in: Cell proliferation 2016-08, Vol.49 (4), p.409-420
• Main Authors: Liu, Mei, Li, Zhiyang, Yang, Jingjing, Jiang, Yanyun, Chen, Zhongsi, Ali, Zeeshan, He, Nongyue, Wang, Zhifei
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - analysis; Breast - drug effects; Breast - pathology; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Female; Humans; Molecular Targeted Therapy - methods; Review; Reviews
• ISSN: 0960-7722; 1365-2184; 1365-2184
• DOI: 10.1111/cpr.12266

Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell‐specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell‐specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic‐targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non‐antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.